Study details
Enrolling now
A Study of Letermovir to Prevent Cytomegalovirus Infection After Stem Cell Transplant in Children
Children's Oncology Group
NCT IDNCT05711667ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
105
Study length
about 5 years
Ages
2–18
Locations
28 sites in AL, CA, CO +16
What this study is about
This trial is testing whether taking letermovir, an antiviral drug, will reduce the risk of cytomegalovirus (CMV) infection in children after a stem cell transplant. CMV can cause serious illness and this treatment aims to prevent it.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Letermovir
- 2.Undergo Biospecimen Collection
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
letermovir
Drug routes
oral (Oral Tablet)
Procedures
diagnostic
Body systems
Oncology